Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

Denver TMAU Test Lab survey click here
click to Read more/less

USA survey for anyone who wants to improve Denver TMAU test

begun : Dec22
end : no ending for now

A trainee genetic counselor is working at the Denver TMAU test lab. Probably as part of her training. As a project she wishes feedback on any aspect of the Denver TMAU test and process. You can fill in the survey and/or email her (email address is in survey). It's meant for USA people, but perhaps others can give their view too (as we have so few opportunities).

quote from her rareconnect post

"Hello all! I wanted to make you aware of a research study being conducted to better understand the experience and needs of individuals with trimethylaminuria with a goal of being able to create improved patient and healthcare provider education materials. Any participation is completely voluntary and all responses remain confidential. Feel free to use the contact information within the link with any questions or share the survey with others with TMAU."

see this post for more details

Tuesday, June 26, 2012

Dr. Elizabeth Shephard's presentation: FMO3 - a protein that can multi-task

halitosis researchWe are currently working on providing you with Dr. Elizabeth Shephard's powerpoint presentation that she created specifically for the MEBO Conference part of our Miami Beach Meetup 2012. Meanwhile, until we are able to post this in this blog, I would like to offer you a link to it, and a link for you to download FREE QuickTime 7. Please note that QuickTime7 is free, and if you are asked to pay, then you are not in the right place. A web-embedded version of this presentation will be available in several days for me to be able to post it in this blog. Once you have downloaded QuickTime 7, you can run Dr. Shephard's powerpoint presentation using the following link:

This most valuable presentation of data highlights the dangers of certain drugs, including pesticide and psychiatric drugs, for example, for persons who have deficient metabolic clearance. Among those would be persons with FMO3 compromised systems.

Please note, that Dr. Shephard is excited with the new field of genetics called "Pharmacogenetics" which deals with how our genes influence the way we handle a drug. Pharmacogenetics is "Personalized Medicine..." and the focus treatment is "if we understand a person's genetics, can we tailor their drug treatment to get them the best response to their particular drugs."

Dr. Shephard gives us a "very short list" as examples of some FMO3 drug substrates more commonly used, including anaesthetics, a variety of anti-inflammatory (throat lozenges and sprays), anti-psychotic, and neuronal stimulant, such as nicotine. She refers to a study that has proven the inability or compromised ability of people with TMAU to be metabolize Benzydamine.

In addition, she explains how "Many drugs are metabolized by more than one enzyme" including CYPs (P450s).

I highly recommend that all persons, without exception, that suffer from any type of body odor or halitosis condition, study her presentation. All sufferers need to observe and be aware of any adverse reaction to any medication consumed, and to immediately inform their physician.

Dr. Shephard also tells us,

One thing to remember is that many people have unpleasant effects from antipsychotics and antidepressants and this may not be due to changes in FMO3.

This presentation will be put up in this blog as soon as possible.


María de la Torre
Founder and Executive Director

A Public Charity
MEBO's Blog (English)
El Blog de MEBO (español)
MEBO Brasil - Blog (Portuguese)

SUPPORT THE MEBO MISSION: Click Amazon button at right sidebar of this blog when shopping online for the holidays
at no extra cost to you.
MEBO gets small commission from Amazon.

Please use your credit card to make your donation to MEBO.

Subscribe for latest posts : Enter your email address:

Delivered by FeedBurner

A EURORDIS and NORD Member Organization


Post a Comment